About the company
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-stimulating hormone receptor (TSHR) candidate for the treatment of Graves' disease and TED. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcFn) includes VRDN-006, a highly selective Fc fragment, and VRDN-008, a half-life extended bispecific FcRn inhibitor comprising an GC fragment and an albumin-binding domain designed to prolong IGG suppression. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was incorporated in 2010 and is headquartered in Waltham, Massachusetts.
Price history
Monthly close · Moving average The average closing price over a rolling window — a smoothed line that cuts through day-to-day noise to show the trend. A shorter window (say 50 days) reacts quickly; a longer one (200 days, or 12 months) is slower and steadier. Price above its average is often read as strength, below as a relative discount. Learn more →
Dividend profile
Debt & leverage
Latest reported balance-sheet figures.
Held by 1 investor
Sign up for an AI summary of this stock's dividend — and to track it in your portfolio.
Information, not financial advice.